Opioid Treatment Surge Act
This bill requires the Department of Health and Human Services to assess market-share-based fees, for the next 10 years, on drug manufacturers that have produced opioid drugs since 1999. Opioid drugs manufactured to treat opioid addiction, cancer patients, or hospice patients are, however, exempt from this assessment. All assessed fees must be used for the substance abuse prevention and treatment block grant program.
Introduced in House
Introduced in House
Referred to the House Committee on Energy and Commerce.
Referred to the Subcommittee on Health.
Llama 3.2 · runs locally in your browser
Ask anything about this bill. The AI reads the full text to answer.
Enter to send · Shift+Enter for new line